Warren David Shlomchik MD
Hematologic Oncology
Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine
Join to View Full Profile
5115 Centre AvenueBST E1552Pittsburgh, PA 15232
Dr. Shlomchik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1993 - 1997
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989
Certifications & Licensure
PA State Medical License 1993 - 2026
CT State Medical License 2000 - 2015
NY State Medical License 1991 - 1994
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2008
Clinical Trials
- Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD Start of enrollment: 2009 Dec 17
- Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Start of enrollment: 2015 Feb 03
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) Start of enrollment: 2019 Nov 19
Publications & Presentations
PubMed
- IFN-γand donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation .Sawa Ito, Emily Geramita, Kedwin Ventura, Biswas Neupane, Shruti Bhise
JCI Insight. 2025-03-25 - 1 citationsChemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow.Kai Zhao, Jieqing Zhu, Sarah Rosenberger, Meng Zhou, Warren D Shlomchik
Blood Advances. 2025-01-14 - Maintenance strategies for relapse prevention and treatment.Emily Geramita, Jing-Zhou Hou, Warren D Shlomchik, Sawa Ito
Hematology. American Society of Hematology. Education Program. 2024-12-06
Press Mentions
Novel Transplant Approach Improves the Odds for Leukemia PatientsJanuary 10th, 2022
Grant Support
- Phase 2 Study of Interferon-Gamma and Donor Lymphocyte Infusion for the Treatment of Relapsed Myeloid Malignancies after Allogeneic Stem Cell TransplantationUNIVERSITY OF PITTSBURGH AT PITTSBURGH2024–2028
- Phase 2 Study of Interferon-Gamma and Donor Lymphocyte Infusion for the Treatment of Relapsed Myeloid Malignancies after Allogeneic Stem Cell TransplantationUNIVERSITY OF PITTSBURGH AT PITTSBURGH2024–2028
- Graft-versus-Host Disease: Local Maintenance by Tissue Resident Progenitor T cellsUNIVERSITY OF PITTSBURGH AT PITTSBURGH2018–2028
- Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effectUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2025
- Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effectUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2025
- Leukemia Stem Cells: Essential Targets For GVL And Mediators Of Gvl-ResistanceNational Cancer Institute2009–2012
- Role Of Tissue Antigen Presenting Cells In GVHDNational Heart, Lung, And Blood Institute2011
- Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2010
- Dendritic Cell Subsets And Paths Of Maturation In Graft-Vs.-Host Disease (GVHD)National Heart, Lung, And Blood Institute2007–2010
- Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2006–2009
- Graft Versus Leukemia Against Murine Chronic Phase &Blast Crisis CMLNational Cancer Institute2007
- Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Heart, Lung, And Blood Institute2006
- GVL Against Murine Chronic Phase And Blast Crisis CMLNational Cancer Institute2003–2006
- Novel Immunotoxins For Depletion Of Dendritic CellsNational Heart, Lung, And Blood Institute2005
- Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1999–2002
- Pathogenic Mechanisms Of GVD In Murine ModelNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000
- Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
